Drug
Cdx 0159
Cdx 0159: highest development phase Phase 1, developed by Celldex Therapeutics. 4 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Celldex Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| CDX-0159 NCT05031624 | Phase 1 | Healthy Subjects |
| CDX-0159 NCT04538794 | Phase 1 | Chronic Spontaneous Urticaria |
| CDX-0159 NCT04146129 | Phase 1 | Healthy Subjects |
| CDX-0159 NCT04944862 | Phase 1 | Prurigo Nodularis |
Latest
No recent events.
Follow Cdx 0159 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.